| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07340853 CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma |
Recruitment suspended |
| 2026-06-11 | NCT03295383 Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-11 | NCT03295383 Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral… |
Enrollment reduced: 130 -> 92 participants |
| 2026-06-11 | NCT07015242 A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line… |
Trial sites reduced: 82 -> 40 locations |
| 2026-06-09 | NCT07297667 GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory… |
Recruitment opened |
| 2026-06-09 | NCT02621021 A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor… |
Enrollment reduced: 170 -> 53 participants |
| 2026-06-06 | NCT05250973 A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL)… |
date change Primary completion pushed: 2025-05-30 -> 2026-02-04 |
| 2026-06-05 | NCT04579523 ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and… |
date change Primary completion pushed: 2027-12-31 -> 2028-12-31 |
| 2026-06-05 | NCT04579523 ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and… |
date change Completion pushed: 2028-12-31 -> 2029-12-31 |
| 2026-06-05 | NCT06872333 Allo HSCT for High Risk Hemoglobinopathies |
Trial arms changed: 4 -> 5 |
| 2026-06-04 | NCT00379340 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients… |
Trial completed |
| 2026-06-04 | NCT00379340 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients… |
date change Completion moved earlier: 2026-11-18 -> 2026-03-31 |
| 2026-06-04 | NCT06058377 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment… |
date change Primary completion pushed: 2027-05-31 -> 2032-05-31 |
| 2026-06-04 | NCT06058377 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment… |
date change Completion pushed: 2027-05-31 -> 2032-05-31 |
| 2026-06-04 | NCT04989803 Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell… |
Trial sites expanded: 18 -> 21 locations |
| 2026-06-03 | NCT03786783 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly… |
Trial completed |
| 2026-06-03 | NCT03786783 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly… |
date change Completion moved earlier: 2026-09-19 -> 2026-03-31 |
| 2026-06-03 | NCT06500273 Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL |
Trial sites expanded: 68 -> 73 locations |
| 2026-06-03 | NCT05146739 Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients… |
date change Completion pushed: 2026-05-09 -> 2027-05-09 |
| 2026-05-30 | NCT03585465 Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory /… |
Trial terminated |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07641023 Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC | Phase 1/2 | Recruiting |
| 2026-06-11 | NCT07641036 Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer | Phase 1/2 | Recruiting |
| 2026-06-11 | NCT07641049 Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer | Phase 1 | Recruiting |
| 2026-06-11 | NCT07643103 Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative… | Phase 2 | Not Yet Recruiting |
| 2026-06-10 | NCT07638787 Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL | Phase 1/2 | Not Yet Recruiting |
| 2026-06-09 | NCT07634536 Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell… | Phase 2 | Not Yet Recruiting |
| 2026-06-09 | NCT07635342 Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | Phase 2 | Recruiting |
| 2026-06-09 | NCT07636564 Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute… | Phase 2 | Not Yet Recruiting |
| 2026-06-08 | NCT07634471 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | Phase 2/3 | Not Yet Recruiting |
| 2026-06-04 | NCT07627698 Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma | Phase 1/2 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07077486 | Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease | Lupus or SLE | Recruiting |
| NCT05300932 | A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis | Systemic Sclerosis | Active, Not Recruiting |
| Phase 3 | |||
| NCT06220032 | Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With… | DLBCL - Diffuse Large B Cell Lymphoma | Recruiting |
| NCT07362914 | Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions | Breast Cancer | Recruiting |
| NCT06983821 | Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis… | Granulomatosis With Polyangiitis | Recruiting |
| NCT07388602 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib… | Amyloidosis | Recruiting |
| NCT07174427 | Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With… | Synovial Sarcomas | Recruiting |
| NCT03126916 | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With… | Ganglioneuroblastoma | Recruiting |
| NCT06744504 | Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid… | AML | Recruiting |
| NCT06072612 | Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast… | Breast Cancer | Recruiting |
| NCT07441460 | A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable… | Resectable HER2-positive Breast Cancer | Recruiting |
| NCT07168161 | BDB-001 Phase III Trial in ANCA-Associated Vasculitis | ANCA Associated Vasculitis (AAV) | Recruiting |
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk… | B Acute Lymphoblastic Leukemia | Recruiting |
| NCT05304585 | Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low… | Embryonal Rhabdomyosarcoma | Recruiting |
| NCT05382338 | A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Childhood Medulloblastoma | Recruiting |
| NCT06401330 | A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology… | Stage I Mixed Cell Type Kidney Wilms Tumor | Recruiting |
| NCT06647953 | Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary… | Pleuropulmonary Blastoma | Recruiting |
| NCT04043494 | International Cooperative Treatment Protocol for Children and Adolescents With… | Lymphoblastic Lymphoma, Childhood | Recruiting |
| NCT06022939 | Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone… | AL Amyloidosis | Recruiting |
| NCT06413498 | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants… | Multiple Myeloma | Recruiting |
| NCT07479797 | Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants… | Relapsed or Refractory Large B-cell Lymphoma | Recruiting |
| NCT06091865 | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it… | Diffuse Large B-cell Lymphoma (DLBCL) | Recruiting |
| NCT07335562 | A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel /… | Systemic Sclerosis | Recruiting |
| NCT05183035 | Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | Recruiting |
| NCT06091254 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works… | Follicular Lymphoma (FL) | Recruiting |